Proton pump inhibitors do not increase the risk of acute rejection

Netherlands Journal of Medicine

Volumn 72, Issue 2, 2014, Pages 86-90

  van Boekel, G A J ^a   Kerkhofs, C H H ^a   van de Logt, F ^a   Hilbrands, L B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute rejection; Kidney transplantation; Mycophenolate mofetil; Proton pump inhibitor

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; COTRIMOXAZOLE; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PANTOPRAZOLE; PREDNISONE; RANITIDINE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BIOPSY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GLOMERULUS FILTRATION RATE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PROTEINURIA; RETROSPECTIVE STUDY; ULCER; ACUTE DISEASE; FOLLOW UP; GRAFT REJECTION; INCIDENCE; KIDNEY; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACUTE DISEASE; BIOPSY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NETHERLANDS; PROTON PUMP INHIBITORS; RANITIDINE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84895826490     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-6.
2. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079-83.
3. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-503.
4. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043-51.
5. Logan AJ, Morris-Stiff GJ, Bowrey DJ, Jurewicz WA. Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study. Clin Transplant. 2002;16:163-7.
6. Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Therapeutic Drug Monit. 2008;30:46-51.
7. Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28:605-11.
8. Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49:1196-201.
9. Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010;42:4243-6.
10. Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology. 2010;49:2061-7.
11. Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009;9:1650-6.
12. Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52:1265-72.
13. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Therapeut. 1994;8:193-201.
14. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol. 1999;94:351-7.
15. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-60.
16. Tutuian R, Katz PO, Bochenek W, Castell DO. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther. 2002;16:829-36.
17. Lidgate D, Brandl M, Holper M, Abubakari A, Wu X. Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. Drug Dev Ind Pharm. 2002;28:1275-83.
18. Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Therapeutic Drug Monit. 2011;33:120-3.
19. van Gelder T, Tedesco Silva H, de Fijter JW, et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation. 2010;89:595-9.
20. David-Neto E, Takaki KM, Agena F, et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. Therapeutic Drug Monit. 2012;34:331-6.